MedTrace Logo

MRI for Screening and Monitoring Scleroderma ILD

NCT05204355 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-05-01

No results posted yet for this study

Summary

The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.

Conditions

  • Scleroderma

Interventions

DIAGNOSTIC_TEST

MRI

Patients will be imaged using MRI

DRUG

Hyperpolarized Xe129

Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.

DIAGNOSTIC_TEST

HRCT

High Resolution Computer Tomography

Sponsors & Collaborators

  • Scleroderma Foundation

    collaborator UNKNOWN

  • University of Kansas Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2025-03-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05204355 on ClinicalTrials.gov